Technology Access Fees. In consideration for the exclusive rights granted under the Agreement, Pioneer will pay NBY the following amounts as set forth below:
Technology Access Fees. In further consideration for the Research License and for the access to the FivePrime Background Know-How during the Research Term, UCB shall pay to FivePrime non-refundable technology access fees. The technology access fees will be payable as three (3) equal payments of two million two hundred thousand dollars ($2,200,000) each, to be due and payable as follows: (a) within *** Business Days after the Effective Date; (b) on the first anniversary of the Effective Date; and (c) on the second anniversary of the Effective Date.
Technology Access Fees. The parties acknowledge that, to implement the Agreement, as modified by this Amendment, xxxxxx.xxx requires, and shall have, access to unique technologies owned by RealSelect and incorporated into the Web Sites and the servers hosting the Web Sites. As consideration for its access to these unique technologies, subject to Section 6 above, xxxxxx.xxx shall pay to RealSelect a monthly technology access fee (collectively, the "Technology Access Fees") in accordance with the following schedule: (i) for the twelve (12) month period commencing on June 30, 1999, [*] per month; (ii) for the twelve (12) month period commencing on June 30, 2000, [*] per month; and (iii) for the balance of the Initial Term, [*] per month. Xxxxxx.xxx shall make payments of all Technology Access Fees net thirty (30) days from the end of the month for which such payment was due.
Technology Access Fees. (a) ImmunoGen shall pay Raven [ * ] in cash within [ * ] after [ * ].
Technology Access Fees. Kite shall pay Alpine a technology access fee of Five Million Dollars ($5,000,000) within thirty (30) days after the Effective Date. The technology access fee paid by Kite to Alpine under this Section 3.1(b) will be noncreditable and nonrefundable[…***…].
Technology Access Fees. The provisions of this Section 3.3 shall apply for each Designated Gene included within the scope of the Genentech License. Beginning on the anniversary of the Effective Date that is at least [***] months after the inclusion of such Designated Gene under Section 2.1(e), and on each anniversary of the Effective Date thereafter, Genentech shall pay to Sangamo an annual technology access fee of [***] (“Technology Access Fee”) for such Designated Gene; provided, however, the Technology Access Fee for such Designated Gene shall no longer be due after [***]. For clarity, Genentech shall not have any obligation to pay a Technology Access Fee for any Designated Gene for which the Genentech License was terminated under Section 8.3.
Technology Access Fees. TDCC shall pay to Biosource a technology access fee of $10,000,000 (ten million U.S. dollars) upon the Effective Date. Within sixty (60) days after the beginning of each of the fourth, fifth, sixth and seventh Contract Year during the Research Collaboration, TDCC shall pay to Biosource an annual technology access fee of $5,000,000 (five million U.S. dollars). Within sixty (60) days after the beginning of the eighth and each subsequent Contract Year during the Research Collaboration, TDCC shall pay to Biosource an annual technology access fee of $10,000,000 (ten million U.S. dollars). All such technology access fees are non-refundable, except the fee shall be refundable in the event that the Agreement is rescinded as provided in Section 12.5.4. For avoidance of doubt, no technology access fee shall be due under this Section 6.1 for any period after the Research Collaboration ends.
Technology Access Fees. TDCC shall pay to Biosource a technology access fee of [*] ([*] U.S. dollars) upon the Effective Date. Within sixty (60) days after the beginning of each of the fourth, fifth, sixth and seventh Contract Year during the Research Collaboration, TDCC shall pay to Biosource an annual technology access fee of [*] ([*] U.S. dollars). Within sixty (60) days after the beginning of the eighth and each subsequent Contract Year during the Research Collaboration, TDCC shall pay to Biosource an annual technology access fee of [*] ([*] U.S. dollars). All such technology access fees are non-refundable, except the fee shall be refundable in the event that the Agreement is rescinded as provided in Section 12.5.4. For avoidance of doubt, no technology access fee shall be due under this Section 6.1 for any period after the Research Collaboration ends.
Technology Access Fees. Three (3) months after the Effective Date, Genentech shall pay to Sangamo an initial technology access fee of $[***]. Thereafter, on each anniversary of the Effective Date (starting with the first anniversary) prior to the First Commercial Sale of the first Licensed Product, Genentech shall pay to Sangamo an annual technology access fee of $[***].
Technology Access Fees. Subject to the terms and conditions of this Agreement, the Company has agreed to pay a Technology Access Fee (as defined in the Channel Agreement) valued at three million dollars ($3,000,000) to Intrexon, which Technology Access Fee may be paid either in cash or Company’s Common Stock at Company’s sole discretion. Payment for the Technology Access Fee will be made at the Closing (as hereinafter defined) in accord with this Section 1.1. Company, in its discretion, shall either (i) pay to Intrexon three million dollars ($3,000,000) cash at the Technology Access Fee Closing (as defined below), or (ii) pay Intrexon at the Technology Access Fee Closing the Technology Access Fee due by issuing to Intrexon twenty-four million (24,000,000) shares of Common Stock of Company (the “Technology Access Fee Shares”) in accord with this Section 1.1.
